迪哲医药：专注小分子原始创新，差异化管线厚积薄发

Investment Rating - The report gives a "Buy" rating for the company with a target price of 60.09 CNY per share [6] Core Views - The company focuses on original innovation in small molecule drugs, particularly in the oncology field, with 6 globally competitive product pipelines and 2 commercialized products [3] - Sunvozertinib (舒沃替尼) is the first domestically developed drug for EGFR Exon20ins mutation NSCLC, filling a treatment gap and has submitted an NDA to the FDA [4] - Golvatinib (戈利昔替尼) is the first JAK1 inhibitor approved for R/R PTCL, offering advantages in efficacy and safety [4] - Early-stage pipelines like DZD8586 (BTK/LYN inhibitor) and DZD2269 (A2aR antagonist) show potential for overcoming drug resistance and providing new treatment options [5] Financial Forecasts - Revenue is expected to grow from 540 million CNY in 2024 to 1.684 billion CNY in 2026, driven by core product sales [5] - EPS is projected to improve from -2.19 CNY in 2024 to -0.50 CNY in 2026 [5] Company Overview - The company specializes in small molecule drug R&D, with a focus on oncology and immunology, and has a strong management team with extensive industry experience [44][45] - It has established 6 globally competitive product pipelines, with 2 products already commercialized [44] Product Pipeline - Sunvozertinib: Approved in China for EGFR Exon20ins mutation NSCLC, with global Phase III trials ongoing [4][44] - Golvatinib: Approved in China for R/R PTCL, with potential for first-line maintenance therapy [4][96] - DZD8586: A novel BTK/LYN inhibitor with potential to overcome BTK resistance, currently in Phase I/II trials [5][52] - DZD2269: A selective A2aR antagonist in Phase I trials for prostate cancer [5] - DZD1516: A HER2 inhibitor with blood-brain barrier penetration, effective for heavily pretreated HER2+ breast cancer [5] Market and Industry Analysis - EGFR Exon20ins mutation NSCLC represents a significant unmet clinical need, with Sunvozertinib being the first domestically developed drug targeting this mutation [57][58] - PTCL has a poor prognosis, and Golvatinib is the only JAK1 inhibitor approved for this indication, offering a new treatment option [96] - BTK inhibitors have revolutionized the treatment of B-cell lymphomas, but resistance remains a challenge, which DZD8586 aims to address [105][106]